Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines

Hiroyuki Inoue, Mutsunori Murahashi, Haruka Nabeta, Tomoko Yokoo, Yoko Suehiro, Shinji Okano, Makoto Inoue, Hiroaki Kinoh, Toyomasa Katagiri, Koichi Takayama, Yoshikazu Yonemitsu, Mamoru Hasegawa, Yusuke Nakamura, Yoichi Nakanishi, Kenzaburo Tani

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The recent clinical application of granulocyte macrophage colony-stimulating factor (GM-CSF)-transduced autologous tumor vaccines revealed substantial antitumor activity and valuable clinical results. However, for these vaccines to be optimally effective, the antitumor efficacies must be improved. Recently, Sendai virus (SeV) vectors, which are cytoplasmic RNA vectors, have emerged as safe vectors with high gene transduction. In the current study, the in.vivo therapeutic antitumor efficacies of irradiated GM-CSF-transduced mouse renal cell carcinoma (RENCA) vaccine cells mediated by either fusion gene-deleted non-transmissible SeV encoding mouse GM-CSF (SeV/dF/G) or adenovirus (E1, E3 deleted serotype 5 adenovirus) encoding mouse GM-CSF (AdV/G) (respectively described as irRC/SeV/GM or irRC/AdV/GM) were compared in RENCA-bearing mice. The results showed that the antitumor effect was equivalent between irRC/SeV/GM and irRC/AdV/GM cells, even though the former produced less GM-CSF in vitro. The cell numbers of activated (CD80+, CD86+, CD80+ CD86+) dendritic cells in lymph nodes from mice treated with irRC/AdV/GM or irRC/SeV/GM cells were increased significantly compared with those of mice treated with the respective controls, at both the earlier and later phases. In an in.vitro cytotoxicity assay, splenocytes harvested from mice treated with both irRC/SeV/GM and irRC/AdV/GM cells showed tumor-specific responses against RENCA cells. The restimulated splenocytes harvested from mice treated with irRC/SeV/GM or irRC/AdV/GM cells produced significantly higher levels of interleukin-2, interleukin-4, and interferon-γ compared with their respective controls (P < 0.05). Furthermore, vaccination with irRC/AdV/GM or irRC/SeV/GM cells induced significantly enhanced recruitment of the cytolytic effectors of CD107a +CD8+ T cells and CD107a+ natural killer cells into tumors compared with those induced by their respective controls (P < 0.05). Taken together, our results suggest that the SeV/dF/G vector is a potential candidate for the production of effective autologous GM-CSF-transduced tumor vaccines in clinical cancer immune gene therapy.

Original languageEnglish
Pages (from-to)2315-2326
Number of pages12
JournalCancer Science
Volume99
Issue number11
DOIs
Publication statusPublished - Nov 11 2008

Fingerprint

Sendai virus
Cancer Vaccines
Granulocyte-Macrophage Colony-Stimulating Factor
Renal Cell Carcinoma
Adenoviridae
Vaccines
Neoplasm Genes
Gene Fusion
Natural Killer Cells
Interleukin-4
Genetic Therapy
Dendritic Cells
Interferons
Interleukin-2
Neoplasms
Vaccination
Cell Count
Lymph Nodes
RNA
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. / Inoue, Hiroyuki; Murahashi, Mutsunori; Nabeta, Haruka; Yokoo, Tomoko; Suehiro, Yoko; Okano, Shinji; Inoue, Makoto; Kinoh, Hiroaki; Katagiri, Toyomasa; Takayama, Koichi; Yonemitsu, Yoshikazu; Hasegawa, Mamoru; Nakamura, Yusuke; Nakanishi, Yoichi; Tani, Kenzaburo.

In: Cancer Science, Vol. 99, No. 11, 11.11.2008, p. 2315-2326.

Research output: Contribution to journalArticle

Inoue, H, Murahashi, M, Nabeta, H, Yokoo, T, Suehiro, Y, Okano, S, Inoue, M, Kinoh, H, Katagiri, T, Takayama, K, Yonemitsu, Y, Hasegawa, M, Nakamura, Y, Nakanishi, Y & Tani, K 2008, 'Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines', Cancer Science, vol. 99, no. 11, pp. 2315-2326. https://doi.org/10.1111/j.1349-7006.2008.00964.x
Inoue, Hiroyuki ; Murahashi, Mutsunori ; Nabeta, Haruka ; Yokoo, Tomoko ; Suehiro, Yoko ; Okano, Shinji ; Inoue, Makoto ; Kinoh, Hiroaki ; Katagiri, Toyomasa ; Takayama, Koichi ; Yonemitsu, Yoshikazu ; Hasegawa, Mamoru ; Nakamura, Yusuke ; Nakanishi, Yoichi ; Tani, Kenzaburo. / Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. In: Cancer Science. 2008 ; Vol. 99, No. 11. pp. 2315-2326.
@article{693f7e368fa248fd95911e96de85f373,
title = "Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines",
abstract = "The recent clinical application of granulocyte macrophage colony-stimulating factor (GM-CSF)-transduced autologous tumor vaccines revealed substantial antitumor activity and valuable clinical results. However, for these vaccines to be optimally effective, the antitumor efficacies must be improved. Recently, Sendai virus (SeV) vectors, which are cytoplasmic RNA vectors, have emerged as safe vectors with high gene transduction. In the current study, the in.vivo therapeutic antitumor efficacies of irradiated GM-CSF-transduced mouse renal cell carcinoma (RENCA) vaccine cells mediated by either fusion gene-deleted non-transmissible SeV encoding mouse GM-CSF (SeV/dF/G) or adenovirus (E1, E3 deleted serotype 5 adenovirus) encoding mouse GM-CSF (AdV/G) (respectively described as irRC/SeV/GM or irRC/AdV/GM) were compared in RENCA-bearing mice. The results showed that the antitumor effect was equivalent between irRC/SeV/GM and irRC/AdV/GM cells, even though the former produced less GM-CSF in vitro. The cell numbers of activated (CD80+, CD86+, CD80+ CD86+) dendritic cells in lymph nodes from mice treated with irRC/AdV/GM or irRC/SeV/GM cells were increased significantly compared with those of mice treated with the respective controls, at both the earlier and later phases. In an in.vitro cytotoxicity assay, splenocytes harvested from mice treated with both irRC/SeV/GM and irRC/AdV/GM cells showed tumor-specific responses against RENCA cells. The restimulated splenocytes harvested from mice treated with irRC/SeV/GM or irRC/AdV/GM cells produced significantly higher levels of interleukin-2, interleukin-4, and interferon-γ compared with their respective controls (P < 0.05). Furthermore, vaccination with irRC/AdV/GM or irRC/SeV/GM cells induced significantly enhanced recruitment of the cytolytic effectors of CD107a +CD8+ T cells and CD107a+ natural killer cells into tumors compared with those induced by their respective controls (P < 0.05). Taken together, our results suggest that the SeV/dF/G vector is a potential candidate for the production of effective autologous GM-CSF-transduced tumor vaccines in clinical cancer immune gene therapy.",
author = "Hiroyuki Inoue and Mutsunori Murahashi and Haruka Nabeta and Tomoko Yokoo and Yoko Suehiro and Shinji Okano and Makoto Inoue and Hiroaki Kinoh and Toyomasa Katagiri and Koichi Takayama and Yoshikazu Yonemitsu and Mamoru Hasegawa and Yusuke Nakamura and Yoichi Nakanishi and Kenzaburo Tani",
year = "2008",
month = "11",
day = "11",
doi = "10.1111/j.1349-7006.2008.00964.x",
language = "English",
volume = "99",
pages = "2315--2326",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines

AU - Inoue, Hiroyuki

AU - Murahashi, Mutsunori

AU - Nabeta, Haruka

AU - Yokoo, Tomoko

AU - Suehiro, Yoko

AU - Okano, Shinji

AU - Inoue, Makoto

AU - Kinoh, Hiroaki

AU - Katagiri, Toyomasa

AU - Takayama, Koichi

AU - Yonemitsu, Yoshikazu

AU - Hasegawa, Mamoru

AU - Nakamura, Yusuke

AU - Nakanishi, Yoichi

AU - Tani, Kenzaburo

PY - 2008/11/11

Y1 - 2008/11/11

N2 - The recent clinical application of granulocyte macrophage colony-stimulating factor (GM-CSF)-transduced autologous tumor vaccines revealed substantial antitumor activity and valuable clinical results. However, for these vaccines to be optimally effective, the antitumor efficacies must be improved. Recently, Sendai virus (SeV) vectors, which are cytoplasmic RNA vectors, have emerged as safe vectors with high gene transduction. In the current study, the in.vivo therapeutic antitumor efficacies of irradiated GM-CSF-transduced mouse renal cell carcinoma (RENCA) vaccine cells mediated by either fusion gene-deleted non-transmissible SeV encoding mouse GM-CSF (SeV/dF/G) or adenovirus (E1, E3 deleted serotype 5 adenovirus) encoding mouse GM-CSF (AdV/G) (respectively described as irRC/SeV/GM or irRC/AdV/GM) were compared in RENCA-bearing mice. The results showed that the antitumor effect was equivalent between irRC/SeV/GM and irRC/AdV/GM cells, even though the former produced less GM-CSF in vitro. The cell numbers of activated (CD80+, CD86+, CD80+ CD86+) dendritic cells in lymph nodes from mice treated with irRC/AdV/GM or irRC/SeV/GM cells were increased significantly compared with those of mice treated with the respective controls, at both the earlier and later phases. In an in.vitro cytotoxicity assay, splenocytes harvested from mice treated with both irRC/SeV/GM and irRC/AdV/GM cells showed tumor-specific responses against RENCA cells. The restimulated splenocytes harvested from mice treated with irRC/SeV/GM or irRC/AdV/GM cells produced significantly higher levels of interleukin-2, interleukin-4, and interferon-γ compared with their respective controls (P < 0.05). Furthermore, vaccination with irRC/AdV/GM or irRC/SeV/GM cells induced significantly enhanced recruitment of the cytolytic effectors of CD107a +CD8+ T cells and CD107a+ natural killer cells into tumors compared with those induced by their respective controls (P < 0.05). Taken together, our results suggest that the SeV/dF/G vector is a potential candidate for the production of effective autologous GM-CSF-transduced tumor vaccines in clinical cancer immune gene therapy.

AB - The recent clinical application of granulocyte macrophage colony-stimulating factor (GM-CSF)-transduced autologous tumor vaccines revealed substantial antitumor activity and valuable clinical results. However, for these vaccines to be optimally effective, the antitumor efficacies must be improved. Recently, Sendai virus (SeV) vectors, which are cytoplasmic RNA vectors, have emerged as safe vectors with high gene transduction. In the current study, the in.vivo therapeutic antitumor efficacies of irradiated GM-CSF-transduced mouse renal cell carcinoma (RENCA) vaccine cells mediated by either fusion gene-deleted non-transmissible SeV encoding mouse GM-CSF (SeV/dF/G) or adenovirus (E1, E3 deleted serotype 5 adenovirus) encoding mouse GM-CSF (AdV/G) (respectively described as irRC/SeV/GM or irRC/AdV/GM) were compared in RENCA-bearing mice. The results showed that the antitumor effect was equivalent between irRC/SeV/GM and irRC/AdV/GM cells, even though the former produced less GM-CSF in vitro. The cell numbers of activated (CD80+, CD86+, CD80+ CD86+) dendritic cells in lymph nodes from mice treated with irRC/AdV/GM or irRC/SeV/GM cells were increased significantly compared with those of mice treated with the respective controls, at both the earlier and later phases. In an in.vitro cytotoxicity assay, splenocytes harvested from mice treated with both irRC/SeV/GM and irRC/AdV/GM cells showed tumor-specific responses against RENCA cells. The restimulated splenocytes harvested from mice treated with irRC/SeV/GM or irRC/AdV/GM cells produced significantly higher levels of interleukin-2, interleukin-4, and interferon-γ compared with their respective controls (P < 0.05). Furthermore, vaccination with irRC/AdV/GM or irRC/SeV/GM cells induced significantly enhanced recruitment of the cytolytic effectors of CD107a +CD8+ T cells and CD107a+ natural killer cells into tumors compared with those induced by their respective controls (P < 0.05). Taken together, our results suggest that the SeV/dF/G vector is a potential candidate for the production of effective autologous GM-CSF-transduced tumor vaccines in clinical cancer immune gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=55449114286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55449114286&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.00964.x

DO - 10.1111/j.1349-7006.2008.00964.x

M3 - Article

C2 - 18957055

AN - SCOPUS:55449114286

VL - 99

SP - 2315

EP - 2326

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -